Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC
- PMID: 39914919
- DOI: 10.1016/j.jtho.2024.10.018
Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC
Conflict of interest statement
Disclosure Dr. Solomon has served on the advisory board/received honoraria from Eli Lilly, Roche-Genentech, Pfizer, AstraZeneca, Amgen, Bristol Myers Squibb, Merck Sharpe Dohme, Janssen, Takeda, and GlaxoSmithKline. Dr. Hoe declares no conflict of interest.
Publication types
LinkOut - more resources
Full Text Sources
